Post-COVID shifts in Streptococcus pyogenes lineage patterns in Japan
The monthly distribution of Streptococcus pyogenes M1 lineages in Japan changed after the COVID-19 period, with a visible post-pandemic expansion of strains associated with toxic shock syndrome. Figure 2 separates the timeline into pre-COVID-19, COVID-19, and post-COVID-19 periods, and the lineage curves do not stay flat across those phases. They rise, fall, and then reappear in ways that point to altered population dynamics rather than a static background of infection.
One line in the figure is especially hard to ignore: the post-COVID period is not a simple return to baseline. It carries a different mix of M1 lineages, and that mix matters when the clinical syndrome is toxic shock, where invasive disease emerges not just from bacterial presence but from strain-specific virulence potential.
M1UK, M113SNPs, and M1global moved differently across the three periods
The figure tracks three M1 lineages: M1UK, M113SNPs, and M1global. Each lineage is plotted by month, with the y-axis representing the number of calculated 100% isolates of each lineage. The visual separation across time periods suggests that the lineage profile of circulating group A streptococci changed alongside the pandemic era itself.
This kind of shift has direct biological relevance. Streptococcus pyogenes can cause disease through a combination of immune evasion, rapid invasion, and toxin-mediated inflammation. When a lineage expands, the concern is not merely more infections; it is the possibility that a particular genetic background is better equipped to produce the syndromes that drive hospitalization, shock, and organ failure.
The figure format does not provide a clinical case series, treatment outcomes, or patient-level severity scores. Even so, it offers a strong epidemiologic signal: after the COVID-19 period, the M1 lineage landscape in Japan no longer resembles the earlier distribution. The expansion is visible in the months after the vertical line marking the post-COVID period.
Why lineage expansion matters in toxic shock syndrome
Toxic shock syndrome caused by Streptococcus pyogenes is a high-acuity presentation because the organism’s virulence can trigger a disproportionate systemic inflammatory response. A lineage expansion in this setting is more than a microbiologic curiosity. It can foreshadow a broader change in invasive disease burden, especially when the expanding strains belong to a lineage already linked to severe clinical outcomes.
The appearance of M1UK in the figure is particularly important because lineage-specific spread can reflect changes in transmissibility, immune escape, or competitive advantage over older circulating strains. M113SNPs and M1global add another layer of complexity, showing that the M1 population is not monolithic. Different descendants can coexist, and their monthly trajectories can diverge as community transmission patterns change.
That kind of divergence has bedside consequences. When a lineage becomes more common, clinicians and public health teams need to consider whether the observed rise in severe streptococcal syndromes reflects altered exposure patterns, changing host susceptibility, or a strain-level shift in pathogenic potential. The figure does not answer those questions outright, but it sharply narrows the frame in which they must be asked.
The pandemic period likely altered the ecology of circulation
The three-way division into pre-COVID-19, COVID-19, and post-COVID-19 periods signals an epidemiologic break in the circulation of these lineages. Respiratory pathogen ecology changed during the pandemic through masking, distancing, school disruption, travel changes, and altered contact networks. Those pressures can suppress some organisms and reshape which clones are able to persist once routine transmission resumes.
For Streptococcus pyogenes, that ecological reset may have created room for certain M1 lineages to expand. The figure does not assign causation, and it does not need to in order to be clinically meaningful. A surge after a period of suppression can leave a population with lower background immunity, altered strain competition, and a sudden re-entry of more invasive clones into circulation.
The visualized months suggest a dynamic return rather than a gradual restoration of the old order. In infectious diseases, that distinction can define the next wave of cases. A lineage that gains momentum after a disruption can shape the severity profile seen in emergency departments and intensive care units long before the broader pattern is recognized in routine surveillance.
Surveillance must now distinguish strain replacement from simple resurgence
This figure supports a surveillance question that is operationally important: is the post-COVID increase in toxic shock syndrome linked to a rebound of older streptococcal activity, or to actual replacement by more successful lineages? The answer affects how laboratories interpret sequence data, how public health agencies frame alerts, and how clinicians think about the risk behind an apparently routine sore throat or soft tissue infection.
The monthly lineage counts argue for closer genomic tracking, not because every increase signals an outbreak, but because lineage turnover can precede visible clinical change. If M1UK or M113SNPs are expanding within a background of M1global, the circulation pattern itself becomes a marker of evolving invasive disease risk. The figure does not provide the full genetic explanation, yet it is enough to justify continued molecular surveillance of group A streptococci in the post-pandemic era.
What the figure cannot resolve is the exact clinical denominator behind these trends. It does not report total case counts of toxic shock syndrome, the severity of individual infections, or whether lineage expansion translated into worse outcomes at the patient level. Those are the next questions, and they require linked clinical and genomic data rather than lineage plots alone.